Shire enables people with life-debilitating diseases can lead better lives.
Shire Orphan Therapies GmbH is engaged in the discovery, development, and commercialization of peptide-based drugs for disease indications that have limited or no treatment options. The company offers Firazyr (Icatibant) for the treatment of acute attacks of hereditary angioedema in Germany, Austria, Spain, Greece, Denmark, Luxemburg, and the United Ki...
Shire enables people with life-debilitating diseases can lead better lives.
Shire Orphan Therapies GmbH is engaged in the discovery, development, and commercialization of peptide-based drugs for disease indications that have limited or no treatment options. The company offers Firazyr (Icatibant) for the treatment of acute attacks of hereditary angioedema in Germany, Austria, Spain, Greece, Denmark, Luxemburg, and the United Kingdom; and through named patient programs in France, Italy, Norway, and Belgium. Its developing product pipeline includes JSM 6427, a a5ß1 Integrin antagonist for the treatment of cancer, age-related macular degeneration-blindness in the elderly, and angiogenesis, inflammation, and fibrosis; and JSM-7717 and JPE-1375, which are C5a receptor antagonists for the treatment of inflammatory and ophthalmological diseases. The company is also developing JSM 10292, an orally-available small molecule bradykinin B2 receptor antagonist compound for the treatment of chronic and acute disease indications; and Bradykinin B1 receptor antagonist, an orally-available small molecule to treat conditions associated with inflammation and/or pain. In addition, it offers services, such as peptide synthesis and high-throughput screening, as well as produces peptide chips, ready-to-use test kits, and customized tools for exploring protein-protein interactions and identifying new peptide biomarkers. Shire Orphan Therapies GmbH was formerly known as Jerini AG and changed its name to Shire Orphan Therapies GmbH in May 2001, following the acquisition by Shire plc. The company was founded in 1994 and is based in Berlin, Germany. Since September 30, 2008, Shire Orphan Therapies GmbH operates as a subsidiary of Shire plc. We want to help shape the future of health care decisively and create value for patients, physicians, policy makers, payers and our shareholders. Our goal is to improve the quality of life of patients sustained.
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.